With a name change and a new brand identity, US-based company Algos is driving home its shift from a dual-track bioscience business to a pure-play contract research organisation (CRO) focused on preclinical testing in the pain category.

Headquartered in St. Paul, Minneapolis, the company founded in late 2003 has changed its name from Algos Therapeutics to Algos Preclinical Services, in line with its new business model.

Algos also has a new tagline – “Expertise in pain. Legendary service. Definitive results. For better quality of life” – that supports its positioning as the “go-to-CRO” for pain research. An overhaul of the company’s website, a modernised logo and integrated marketing communications materials complete the picture.

Algos’ speciality is preclinical in vivo pain research and programme consulting, spanning experimental design and execution, data analysis and programme management. The company was founded by then president and chief executive officer (CEO) Susanne Clay and chief operating officer/chief scientific officer Dr Todd Verdoorn, neither of whom are now with Algos.

The intention at that time was to pursue a dual strategy of developing breakthrough preclinical compounds to treat chronic pain while exploiting synergistic demand for preclinical pain research services. The drug discovery efforts were based on targets and other intellectual property acquired from Clay’s former company, Neuromics.

The transition to a pure-play CRO was guided by current president and CEO Dr Daniel Menard, who joined Algos in 2007 as chief operating officer. He was previously vice president of pharmacology at another CRO, MDS Pharma Services.